<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032734</url>
  </required_header>
  <id_info>
    <org_study_id>DFI4488</org_study_id>
    <secondary_id>SR121463</secondary_id>
    <secondary_id>LTS5066</secondary_id>
    <secondary_id>LTS10208</secondary_id>
    <nct_id>NCT00032734</nct_id>
  </id_info>
  <brief_title>Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The study is designed to assess the efficacy of an investigational drug called SR121463B
      (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood
      associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).

      This double blind period study is followed by 2 open label extension studies with flexible
      doses of satavaptan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter worldwide study with 32 participating men and women aimed to figure out
      whether SR121463B is safe and effective in correcting low levels of sodium in blood in
      subjects with SIADH. The participation in the study lasts up to 34 days. After screening,
      during the first part of the study (maximum 5 days), the subjects receive either capsules of
      SR121463B or a matching placebo. During the second part of the study (23 days), subjects
      receive either capsules of SR121463B or no treatment. The subjects will be assessed by
      physical examinations, electrocardiograms, blood samplings, and urine collections. Women of
      childbearing potential must have an approved method of contraception.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum sodium concentration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety assessment</measure>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Syndrome of Inappropriate ADH (SIADH) Secretion</condition>
  <condition>Hyponatremia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>satavaptan (SR121463B)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        SIADH of any origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.centerwatch.com</url>
  </link>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2002</study_first_submitted>
  <study_first_submitted_qc>March 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2002</study_first_posted>
  <last_update_submitted>June 16, 2008</last_update_submitted>
  <last_update_submitted_qc>June 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Low Blood Sodium (Hyponatremia)</keyword>
  <keyword>SIADH</keyword>
  <keyword>Inappropriate ADH Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Inappropriate ADH Syndrome</mesh_term>
    <mesh_term>Diabetes Insipidus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Satavaptan</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

